I know, I know.  It’s easy to become numb to the endless new cancer therapy developments that never seem to pan-out.  Well, I believe this one is different.  This is the real deal:

Cell Therapy Shows Promise for Acute Type of Leukemia


By Denise Grady –  Published: March 20, 2013

A treatment that genetically alters a patient’s own immune cells to fight cancer has, for the first time, produced remissions in adults with an acute leukemia that is usually lethal, researchers are reporting.

In one patient who was severely ill, all traces of leukemia vanished in eight days.

“We had hoped, but couldn’t have predicted that the response would be so profound and rapid,” said Dr. Renier J. Brentjens, the first author of a new study of the therapy and a specialist in leukemia at Memorial Sloan-Kettering Cancer Center.

The treatment is experimental, has been used in only a small number of patients and did not work in all of them. But experts consider it a highly promising approach for a variety of malignancies, including other blood cancers and tumors in organs like the prostate gland.

The new study, in five adults with acute leukemia in whom chemotherapy had failed, was published Wednesday in the journal Science Translational Medicine.

The treatment is similar to one that pulled a 7-year-old girl, Emma Whitehead, from death’s door into remission nearly a year ago, and that has had astounding success in several adults with chronic leukemia in whom chemotherapy had failed. The treatment regimen that saved Emma and those adults was developed at the University of Pennsylvania. Related studies have also been done at the National Cancer Institute.

But this cell-therapy approach had not been tried before in adults with the disease that Emma had, acute lymphoblastic leukemia. This type of blood cancer is worse in adults than in children, with a cure rate in adults of only about 40 percent, compared with 80 percent to 90 percent in children. The disease is not common. Each year in the United States, it affects about 2,400 people older than 20, and 3,600 younger. Though there are fewer cases in adults, there are more deaths: about 1,170 adults die each year compared with 270 deaths in people under 20.

In adults, this type of leukemia is a “devastating, galloping disease,” said Dr. Michel Sadelain, the senior author of the new study and director of the Center for Cell Engineering and the Gene Transfer and Gene Expression Laboratory at Memorial Sloan-Kettering Cancer Center in Manhattan.

Michael Nagle for The New York Times David Aponte, at Memorial Sloan-Kettering, had a bone-marrow transplant after T-cell therapy left him in remission in days.

Patients like the ones in the study, who relapse after chemotherapy, usually have only a few months left, Dr. Sadelain said. But now, three of the five have been in remission for 5 to 24 months. Two others died: one was in remission but died from a blood clot, and the other relapsed. The survivors have gone on to have bone-marrow transplants. Their prognosis is good, but relapse is still possible, and only time will tell…

This is only the first part of Ms Grady’s article.  Here’s the link so you can read the rest:


Researchers have been hoping to achieve this type of response using immunotherapy for years.  Could they be getting closer to a broad-based breakthrough?

Feel good and keep smiling!  Pat


Leave a Reply